Continued steady growth：with turnover up 37.9% year-on-year to RMB4,900.8 million and profit for the period up 38.3% year-on-year to RMB1,377.9 million; for the last ten fiscal years, the CAGRs of Group’s turnover and net profit were 32.4% and 40.3% respectively
New product introduction：by introducing Plendil and Imdur from AstraZeneca AB, the product mix is enriched under direct academic network
Steady growth of existing products：insisted on exploiting and supplementing the differentiated academic characteristics of each product, and to comprehensively improve expert network, and refine market strategy
Mid and long-term pipelines： seven products undergoing the IDL application, and two innovative products with the intellectual property rights undergoing the phase III clinical trial, are all progressing smoothly according to the plan
Network coverage：as at 31 December 2016, the Group’s Direct Network had covered more than 38,000 hospitals with around 2,800 professional marketing and promotion sales representatives; the Group’s Agency Network had covered nearly 5,500 hospitals across the country and signed agreements with around 600 agencies or third-party sales representatives
Turnover and profit of the Group for thelast ten fiscal years are listed below:
The Group achieved satisfactory rapid-growth during the Reporting Period. This was on account of the Group’s continuous introduction of new products, quality and diverse product portfolios, well-cultivated and professional academic promotional networks, effective operational management system, as well as its international vision and pragmatic operational approach. Looking ahead, the Group will follow the reform pace of the industry, proactively grasp the opportunities, implement strategic development direction to further improve the internal operation efficiency, drive the solid and sustainable growth of the group and create more value for employees, societies and shareholders.